Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Capital Asset Advisory Services LLC

Capital Asset Advisory Services LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 59.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,402 shares of the company’s stock after acquiring an additional 1,271 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $428,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in NVO. Morgan Stanley lifted its holdings in shares of Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after purchasing an additional 4,526,199 shares during the last quarter. Folketrygdfondet increased its position in shares of Novo Nordisk A/S by 1.4% in the first quarter. Folketrygdfondet now owns 8,756,034 shares of the company’s stock worth $1,124,275,000 after acquiring an additional 124,770 shares in the last quarter. Capital International Investors raised its holdings in shares of Novo Nordisk A/S by 22.3% during the fourth quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock valued at $736,121,000 after acquiring an additional 1,297,536 shares during the period. Royal Bank of Canada lifted its position in shares of Novo Nordisk A/S by 109.2% in the 3rd quarter. Royal Bank of Canada now owns 3,643,061 shares of the company’s stock valued at $331,300,000 after acquiring an additional 1,901,429 shares in the last quarter. Finally, Natixis Advisors L.P. boosted its stake in Novo Nordisk A/S by 1.8% in the 4th quarter. Natixis Advisors L.P. now owns 3,052,406 shares of the company’s stock worth $315,770,000 after purchasing an additional 55,333 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.2 %

NYSE NVO traded down $1.68 during trading on Friday, reaching $142.81. The company’s stock had a trading volume of 2,756,256 shares, compared to its average volume of 4,447,381. The business has a 50-day moving average price of $135.00 and a 200-day moving average price of $123.35. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $148.15. The stock has a market capitalization of $640.86 billion, a PE ratio of 49.24, a PEG ratio of 1.43 and a beta of 0.41. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. On average, research analysts forecast that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NVO. The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price for the company. Argus upped their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. BMO Capital Markets restated an “outperform” rating and set a $163.00 price target on shares of Novo Nordisk A/S in a report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.